Trial Design: How Do We Figure Out if an AED Works

Jacqueline A. French, MD*
Department of Neurology, NYU School of Medicine, 223 East 34th street, NY, NY 10016
*Address correspondence to Jacqueline French, MD, Department of Neurology, NYU School of Medicine, 223 East 34th street, NY, NY 10016.
E-mail: Jacqueline.french@nyumc.org

Regulatory trials rigorously test the ability of a treatment to impact a known outcome, such as seizure frequency, as measured in well-controlled trials. Such outcomes are called efficacy outcomes. Sometimes these measured outcomes do not reflect the true effectiveness of the drug in the clinic. This article provides some examples of how this can happen and also discusses trials intended to measure effectiveness.

In the past 25 years, there has been an explosion in antiepileptic drug (AED) development. Three quarters of the drugs we now use regularly were developed since 1990. Drugs developed and brought to market during this time are often called “second and third generation.” Whereas the older (first-generation) AEDs were not subjected to the rigorous Food and Drug Administration (FDA) standards that are currently in place, the second- and third-generation AEDs have been evaluated in rigorous placebo-controlled trials that have been designed to satisfy regulators, including the FDA, as well as the European Medicines Agency (EMA). These trials provide an initial confirmation that a new AED has a beneficial effect on seizures. However, even after the drug is considered acceptable for approval, there are many questions that remain with respect to clinical use. This review will highlight what is known about a drug as a result of regulatory trials, what remains to be learned, and how additional clinically relevant information can be uncovered.

The Regulatory Path of a New AED
Typically, regulatory authorities require two well-controlled clinical trials to be performed before they will approve a drug for use. The first trials are typically performed in adults with treatment-resistant partial onset seizures. Often, once efficacy has been demonstrated in one indication, approval for further indications (for example, another age group or another epilepsy syndrome) will only require a single trial. These regulatory studies typically enroll treatment-resistant patients who are already on one to three antiepileptic drugs, not including a vagus nerve stimulator, and are having at least three to four countable partial seizures per month. A 6- to 12-week baseline precedes randomization. Patients are then randomized to add-on placebo versus one to three fixed doses of the investigational drug. There is typically a 1- to 4-week titration period, followed by a 12-week maintenance period (1).

Efficacy Versus “Effectiveness”
Do regulatory trials inform us as to whether a drug works? In order to answer this question, it is important to understand the concepts of “efficacy” versus “effectiveness” (2). Efficacy is the term that is used to describe the improvement measured in controlled clinical trials. The term was coined to remind us that this “improvement” may or may not be a reflection of what happens in real life, in the clinic. Why should that be? There are several reasons. For example, “efficacy” is measured with respect to one or two prespecified outcome measures, in a very specific population, over a limited time frame. These factors (selected outcome measure, population, and time frame) can significantly impact the generalizability and usefulness of the information derived from trials. Effectiveness, in contrast, describes the ability of a drug to be useful in the clinic. Regulatory clinical trials are very good for determining efficacy (that is, after all, what these trials are for) but may miss the mark in determining effectiveness, which is what clinicians are most interested in. Several illustrative examples directly related to epilepsy trials are useful to demonstrate this point.

Prespecified Outcome Measure
In order to perform a methodologically sound trial, an outcome measure should be selected in advance, and in fact the regulatory authorities require this. This prerequisite prevents “cherry-picking” one positive outcome from many outcomes, which may be positive, negative, or mixed. This does not mean that regulatory authorities ignore outcomes other than the primary, but this is the one that is scrutinized the most, and the one that is ultimately conveyed in promotional literature and the package insert provided to patients. So, for example, a drug may be shown to cause 35% of patients to experience a 50% reduction in the occurrence of partial-onset seizures, with a statistically significant difference from placebo. But, this number (the drug’s efficacy) can be misleading for a number of reasons. Take, for example, the add-on trial in refractory partial-onset seizures performed to obtain regulatory approval for oxcarbazepine (3). In this trial, 50% of patients on the highest dose, 2,400 mg, had more than...
by a factor of 1.4 (95% confidence interval [CI] 1.0 to 2.0, analysis, the odds of at least a doubling of seizures increased in patients who worsen when randomized to a new AED in comparison with placebo (5). It was presumed that since all the drugs examined in the study had been efficacious, fewer patients would worsen when randomized to active drug than those who were randomized to placebo, and this was correct for the other drugs examined (topiramate, gabapentin, and levetiracetam) but not for tiagabine. In this pooled analysis, the odds of at least a doubling of seizures increased by a factor of 1.4 (95% confidence interval [CI] 1.0 to 2.0, \( p < 0.05 \)) for each increase in dose level above placebo (5). At the highest dose of 48 to 56 mg, 8.9% of patients had a doubling or more, compared with only 3.3% on placebo (5). So, while tiagabine made some patients better, it made others worse. This likely would impact the clinical effectiveness of the drug.

**Population**

Populations who are randomized in regulatory trials are a very select group and differ from the population as a whole. Their epilepsy is quite severe (trials for an indication in add-on partial seizures typically require 3–4 seizures/month), and they have typically failed many drugs before resorting to an investigational agent. Significant psychiatric illness, medical illness, or both often are exclusion criteria. The very old and very young are also excluded. These restrictions limit the generalizability of the trials. In most cases, we have no way of knowing whether patients who do not fit these constraints would fare similarly. Also, to date, regulatory trials have focused on populations that are easier to recruit into trials, namely, treatment-resistant partial-onset seizures, treatment-resistant generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. The effectiveness (or, for that matter, efficacy) of the drugs in other syndromes is often left to determination by trial and error in the clinic.

**Time**

Regulatory trials typically compare treatment arms for only 12 weeks, since patients cannot be maintained on placebo in a blinded trial for a longer time. There is great debate about whether this is really long enough to determine if a drug will work in the clinic. In fact, often the difference between drug and placebo is greatest in the first month of the trial, and by the third month, response in the placebo group and the treatment group is becoming more similar. Is it possible that, given enough time, the two lines would merge? Alternately, it is possible that the treatment may become more effective over time (as has been suggested for the device therapies, including vagus nerve stimulation, deep brain stimulation, and cortical responsive stimulation) (6–8). If either is the case, we will have a great deal of trouble proving it because of the short availability of the control group. Thus, for all we know, the efficacy we measure (over the short term) may be driving us to select drugs that are strong at the outset with no staying power, and rejecting drugs that might be better in the long run.

If determination of efficacy may be misleading, why measure it at all? Why not measure effectiveness from the get-go? Unfortunately it is not that simple. There is an inherent tension between internal and external validity of a trial. By using randomization and an internal control such as placebo, one is able to limit the likelihood that chance, bias, or both have influenced trial outcome. This enhances the likelihood that results are “true” (or valid) and are definitely related to the intervention (the investigational drug). Yet, the very act of controlling and randomizing the study creates an artificiality that may limit the ability to generalize the results to a larger set of circumstances (external validity).

A number of trials have been performed specifically to assess the effectiveness of drugs. Among the most well-known are the Standard and New Antiepileptic Drugs (SANAD) studies. SANAD A compared the standard drug carbamazepine with the newer drugs topiramate, gabapentin, lamotrigine, and oxcarbazepine in patients thought to have partial-onset seizures (9). SANAD B compared the standard drug vaproic acid with the newer drugs lamotrigine and topiramate in patients primarily thought to have idiopathic generalized epilepsy (10). The SANAD studies addressed many of the concerns mentioned above. The study was quite long, and outcome could be examined in many cases over years, not months. The population was varied with respect to age and other characteristics. Since they were enrolled at time of diagnosis, some were treatment sensitive and some ultimately were resistant to treatment. There were several outcome measures, but the primary outcomes were time to treatment failure and time to 1 year seizure remission. Of note, the SANAD study would not be considered as regulatory evidence of drug efficacy since, due to pragmatic reasons (difficulty of masking so many medications, inability to adjust blinded doses) the study was randomized, but not blinded. In addition, no placebo arm was included since the treatments were prescribed in monotherapy. In SANAD A, lamotrigine was determined to be more effective than carbamazepine, not due to superior efficacy (they were about the same), but due to lower likelihood of drop-outs because of side effects. Of note, the most common adverse event associated with treatment failure was rash, and this occurred in 7% of patients allocated to carbamazepine and accounted for 21% of carbamazepine treatment failures. This result compared with a failure rate for rash on lamotrigine of 3%. Rash related to carbamazepine may be associated with both choice of titration rates and dose; and, in the interest of simulating the
"real world," this was left to the physician’s discretion. This information brings into question the certainty of selecting a “drug of choice” based on an effectiveness measure that includes tolerability issues, as they may in fact be able to be improved upon by altering how the drug is administered. Another example of how using a combined efficacy/tolerability measure can muddy the picture is a Veterans Affairs (VA) cooperative study that compared 600 mg of carbamazepine immediate release, versus 150 mg of lamotrigine and 1500 mg of gabapentin in elderly with newly diagnosed seizures. Patients assigned to carbamazepine had a longer time to first seizure but were also more likely to drop out than patients in the other arms, and thus carbamazepine was declared the “loser.” But it is likely that many drop-outs might have been avoided with the use of sustained-release carbamazepine, or titration to a lower target dose (11, 12). These are examples of how, similar to measurement of efficacy, measurement of effectiveness may present issues of interpretation.

The regulatory agencies have drawn their line in the sand, stating their preference for a result that is indisputably “true,” even if it is not particularly clinically informative. And there is some merit to this perspective. One has to begin with a clear demonstration that a drug works at least in one circumstance. For example, in the SANAD study, since there was no substantial difference in the seizure outcomes for carbamazepine and lamotrigine, it could be argued either that neither worked or that both worked equally well. It is for this reason that regulators in the United States do not consider a “no-difference” outcome in a comparative study to be informative.

In summary, one could argue that neither “efficacy” nor “effectiveness” trials alone may be able to inform us about whether drugs are able to improve the symptoms of epilepsy in the clinic, that is, whether they truly “work” in all senses of the word. Relying on efficacy studies alone would be unsatisfying, as they bear so little relationship to most populations and situations that doctors deal with from day to day. Yet, they play a role in the overall determination of whether drugs “work.” It would be inherently dangerous to perform studies of clinical utility (effectiveness) without proof of efficacy first, so that we don’t end up marketing placebo treatments. Evaluating data from both types of trials may eventually provide us with the best information upon which to make treatment decisions.

**Highlights**

The reduction in seizures relative to placebo measured in randomized, controlled regulatory trials may not always reflect the usefulness of a drug in the clinic. The population that is enrolled in regulatory trials may not reflect the variety of patients seen in the clinic, and therefore trial results may not be generalizable.

Clinical regulatory trials give a snapshot of treatment effects over a relatively short duration (several months). Although we presume this will reflect longer term effects, this may not always be the case.

Results from “efficacy” (more artificial, more controlled) and “effectiveness” (more real-world, less controlled) trials need to be combined to see a true picture of treatment effects.

**References**


Disclosure of Potential Conflicts of Interest

Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1 Identifying Information

1. Today’s Date: 2/10/2012
2. First Name Jacqueline Last Name French Degree MD
3. Are you the Main Assigned Author? ☒ Yes ☐ No
   
   If no, enter your name as co-author:

4. Manuscript/Article Title: Benzo vs benzo: and the winner is…
5. Journal Issue you are submitting for: 11.5

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☐</td>
<td></td>
<td>$0.00</td>
<td>JAZZ, Upsher-Smith</td>
<td>TESC (Consortium) received funding for work performed</td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
Section #3  Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation.</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4  Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☐ No other relationships/conditions/circumstances that present a potential conflict of interest.
☒ Yes, the following relationships/conditions/circumstances are present:

I receive 25% salary support for my work for the Consortium, but this is from work performed for 10 companies, not just the two listed which have projects related to benzodiazepines.

Thank you for your assistance.